Highlight why customers choose Talima Therapeutics's products and services with an Analyst Briefing
Compete with Talima Therapeutics?
Brief our analysts.
Get in front of tech buyers.
No pay-to-play nonsense.
Compare Talima Therapeutics to Competitors
EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.
Glycologic Limited is a company dedicated to the creation of nutritional, clinical nutrition and drug delivery systems based on carbohydrates which overcome the limitations of other technologies. The Company utilises the properties of carbohydrates to develop customised solutions to a wide variety of nutritional and pharmaceutical problems.
Core Tech Solutions, Inc. is engaged in the development of Transdermal, Dermal and Tran mucosal Delivery Systems for the treatment of a variety of indications. The primary mission of the company is to provide transdermal drug delivery development to the worlds pharmaceutical companies. In addition to offering research and development on a contractual basis, Core Tech Solutions possesses the facilities and expertise to perform or coordinate all other aspects of commercialization including Feasibility Studies, Prototype Development, Formulation Optimization, Clinical Trials, Regulatory Compliance, Process Scale-up, and Full Scale Manufacturing.
POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphere. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphere, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques.
Selective Amplifier Genes offers artificial genes that improve the functions of vectors for use in blood disorders
BrainsGate develops a technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.)
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.